Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  International Journal of Oncology

• Publication date

  1993-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/IJO.3.1.57PMID 21573326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases.

  1991cited by this paper
• Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P‐30 protein, a novel protein possessing anti‐tumour activity

  1990cited by this paper
• Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos.

  1990cited by this paper
• Cytostatic and Cytotoxic Effects of Pannon (P‐30 Protein), A Novel Anticancer Agent

  1988cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Preparation, expression, and anti-cancer effects of the novel fusion protein rONC-T7-pHLIP

  2025cites this paper
• Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections

  2022cites this paper
• Promises of eukaryotic ribonucleases for cancer treatment: a systematic review

  2022cites this paper
• Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents

  2021cites this paper
• Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy.

  2021cites this paper
• Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.

  2019cites this paper
• Improving the specific antitumor efficacy of ONC by fusion with N-terminal domain of transferrin

  2018cites this paper
• Targeted delivery of immuno-RNase may improve cancer therapy

  2018cites this paper
• Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells

  2018cites this paper
• Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives.

  2017cites this paper
• Antiviral effect of ranpirnase against Ebola virus.

  2016cites this paper
• Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.

  2016cites this paper
• Resistance to Immunotoxins in Cancer Therapy

  2015cites this paper
• An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.

  2015cites this paper
• Angiogenin Mutants as Novel Effector Molecules For the Generation of Fusion Proteins With Increased Cytotoxic Potential

  2015cites this paper
• A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells

  2015cites this paper
• Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

  2015cites this paper
• Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer

  2014cites this paper
• A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.

  2014cites this paper
• Impact of Folic Acid Supplementation on Single- and Double-Stranded RNA Degradation in Human Colostrum and Mature Milk

  2014cites this paper
• RC-6 ribonuclease induces caspase activation, cellular senescence and neuron-like morphology in NT2 embryonal carcinoma cells.

  2014cites this paper
• Antibody‐Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins

  2014cites this paper
• In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line.

  2013cites this paper
• Formulation and Evaluation of Hybrid Onconase Nanoparticles for treatment of Mesothelioma

  2013cites this paper
• Ribonucleases as Novel Chemotherapeutics

  2012cites this paper
• Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

  2010cites this paper
• Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent

  2010cites this paper
• [Onconase: a ribonuclease with antitumor activity].

  2010cites this paper
• Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy

  2009cites this paper
• Ribonucleases and immunoRNases as anticancer drugs.

  2009cites this paper
• Ranpirnase (Onconase®), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy

  2008influential citation
• Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.

  2008cites this paper
• Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

  2008cites this paper
• Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

  2008cites this paper
• Antibody-onconase conjugates: cytotoxicity and intracellular routing.

  2008cites this paper
• The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma

  2008cites this paper
• Ribonucleases as novel chemotherapeutics : the ranpirnase example.

  2008cites this paper
• Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.

  2006cites this paper
• Transfer RNA Cleavages by Onconase Reveal Unusual Cleavage Sites*

  2006cites this paper
• Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma

  2006influential citation
• Indigenous enzymes in milk: Overview and historical aspects—Part 1

  2006cites this paper
• The Role of Chemotherapy in the Management of Mesothelioma

  2006cites this paper
• RIBONUCLEASAS: SU POTENCIAL TERAPÉUTICO EN INFECCIONES VIRALES Ribonucleases: Theurapetical potential on Viral Infections

  2006cites this paper
• Ribonuclease inhibitor: structure and function.

  2005cites this paper
• Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.

  2005cites this paper
• Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase

  2005cites this paper
• Targeting malignant B‐cell lymphoma with a humanized anti‐CD22 scFv‐angiogenin immunoenzyme ‡

  2005cites this paper
• Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.

  2005cites this paper
• Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase.

  2004cites this paper
• A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

  2004cites this paper
• Effect of N-terminal and Met23 Mutations on the Structure and Dynamics of Onconase*

  2004cites this paper
• Glycosylation of onconase increases its conformational stability and toxicity for cancer cells.

  2004cites this paper
• Oligomerization of bovine ribonuclease A: structural and functional features of its multimers.

  2004cites this paper
• The Rapeutic Antibodies and Antibody Fusion Proteins

  2003cites this paper
• Compensating effects on the cytotoxicity of ribonuclease A variants.

  2003cites this paper
• RNA cleavage and inhibition of protein synthesis by bleomycin.

  2003cites this paper
• ONCONASE® and Its Therapeutic Potential

  2003cites this paper
• Indigenous Nucleases in Milk

  2003cites this paper
• Indigenous Enzymes in Milk

  2003cites this paper
• KFERQ Sequence in Ribonuclease A-mediated Cytotoxicity*

  2002cites this paper
• Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics

  2002cites this paper
• Designing immunotoxins for cancer therapy

  2002cites this paper
• Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents

  2002cites this paper
• Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family*

  2002cites this paper
• Phase I I T rial o f a S ingle W eekly I ntravenous D ose o f Ranpirnase i n P atients W ith U nresectable M alignant Mesothelioma

  2002cites this paper
• Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells.

  2002cites this paper
• Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

  2002cites this paper
• Targeting the CD22 Receptor with RNA Damaging Agents

  2002cites this paper
• Ribonucleases and their antitumor activity.

  2001cites this paper
• Selective activity of BS-RNase against anaplastic thyroid cancer.

  2001cites this paper
• Effect of P-30 protein and tamoxifen on transforming growth factor-β1 in patients with rising prostate specific antigen

  2001cites this paper
• Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.

  2001cites this paper
• Endowing Human Pancreatic Ribonuclease with Toxicity for Cancer Cells*

  2001cites this paper
• Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA

  2001cites this paper
• Interaction of Human Pancreatic Ribonuclease with Human Ribonuclease Inhibitor

  2001cites this paper
• Cancer chemotherapy--ribonucleases to the rescue.

  2001cites this paper
• Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.

  2001cites this paper
• Antibody-Enzyme Fusions

  2001cites this paper
• Bovine seminal ribonuclease inhibits in vivo growth of human neuroblastoma cells.

  2000cites this paper
• Localization and analysis of nonpolar regions in onconase

  2000cites this paper
• A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3' UTR of unusual length and structure.

  2000cites this paper
• Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases.

  1999cites this paper
• Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake

  1999cites this paper
• Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.

  1999cites this paper
• Natural and engineered cytotoxic ribonucleases: therapeutic potential.

  1999cites this paper
• Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction

  1999cites this paper
• Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability.

  1999cites this paper
• Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor.

  1999cites this paper
• A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells.

  1999cites this paper
• Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis.

  1999cites this paper
• Ribonuclease A variants with potent cytotoxic activity.

  1998cites this paper
• Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties.

  1998cites this paper
• Continuing the fight against advanced colorectal cancer: new and future treatment options.

  1998cites this paper
• Ribonuclease inhibits Kaposi's sarcoma

  1997cites this paper
• 15 – Antitumor RNases

  1997cites this paper
• Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy.

  1997cites this paper
• Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo.

  1996cites this paper
• Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.

  1996cites this paper
• Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.

  1996cites this paper
• Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily.

  1996cites this paper